
businessMay 5, 20266:01pending
Light Science Technologies' Injectaclad acquisition drives first major order
About this episode
Light Science Technologies Holdings PLC (AIM:LST, FRA:9FD) CEO Simon Deacon tells Proactive's Stephen Gunnion that the company has landed its first order since acquiring Injectaclad — a £410,000 contract to supply fire protection materials for a five-storey residential building.
Deacon explains what sets Injectaclad apart: it eliminates the need to remove a building's façade, making it around ten times cheaper and six to seven times faster than traditional remediation, with no disruption to residents.
The commercial opportunity is substantial. The company is working with 11 installers nationwide, has a quoted pipeline of around £130 million, and is targeting a market of over 40,000 UK buildings requiring remedial fire protection work, with improving approval timelines from the Building Safety Regulator helping projects move faster.
For more insights like this, visit Proactive’s YouTube channel, like the video, subscribe, and enable notifications so you never miss future updates.
#LightScienceTechnologies #Injectaclad #FireSafety #Cladding #BuildingSafety #ConstructionUK #StockMarketNews #SmallCapStocks #Infrastructure #FireProtection #UKHousing #InvestorNews #CEOInterview
Get every episode summarized
Each time Proactive - Interviews for investors publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Proactive - Interviews for investors

Titan Minerals extends gold-silver mineralisation at Dynasty
Proactive - Interviews for investors
Sep 9, 20263:46failed

Krakatoa Resources: Zopkhito drilling extends gold-antimony potential
Proactive - Interviews for investors
Sep 9, 20264:07failed

Gaming Realms CEO: Content growth accelerating as company expands into new marke...
Proactive - Interviews for investors
Sep 9, 20262:59failed

genedrive CEO: NHS adoption and global expansion drive point-of-care testing pus...
Proactive - Interviews for investors
Sep 9, 20268:49failed